Figure S4

(a) ATP signal in HCT116 cells treated with various concentrations of GDC-0994 and cobimetinib combinations.

(b) ATP signal in HCT116 cells treated with various concentrations of GDC-0994 and selumetinib combinations.

(c) ATP signal in HCT116 cells treated with various concentrations of GDC-0994 and trametinib combinations.
Supplemental Figure 4. Combination of different MEK and ERK inhibitors results in combination anti-proliferative activity.

(a) Cell viability in HCT116 (KRAS<sup>G13D</sup>, colorectal) cells were treated with cobimetinib and four different ERK inhibitors, GDC-0994, SCH772984, Vx-11e, and ulixertinib (BVD-523) at the indicated concentrations and cell viability was measured after 72 hr of culture (CellTiter-Glo®). (b) Cell viability in HCT116 (KRAS<sup>G13D</sup>, colorectal) cells were treated with GDC-0994 and four different MEK inhibitors, GDC-0623, selumetinib, binimetinib, and trametinib at the indicated concentrations and cell viability was measured after 72 hr of culture (CellTiter-Glo®). Studies were run concurrently with some curves represented more than once for ease of comparison.